Medexus Pharmaceuticals Inc. (MEDXF) PT Lowered to $7 at Roth Capital
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 11/4/2026
- Nasdaq ends higher as AI heavyweights rebound ahead of midterm results
- Apple shares slip amid guidance for tightening margins, slowing services growth
- Rising shorts cool U.S. large-cap positioning, cutting liquidation risk: Citi
- Apple's 'unprecedented' memory warning adds fuel to wobbly Micron, SK hynix trade
- Palantir raises 2026 revenue outlook after quarterly revenue nearly doubles on AI
Tweet
Share
E-mailGet Alerts MEDXF Hot Sheet
Price: $3.56 +4.40%
Rating Summary:
1 Buy, 0 Hold, 0 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 15 | Down: 22 | New: 15
Rating Summary:
1 Buy, 0 Hold, 0 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 15 | Down: 22 | New: 15
Join SI Premium – FREE
Roth Capital analyst Scott Henry lowered the price target on Medexus Pharmaceuticals Inc. (OTC: MEDXF) to $7.00 (from $8.00) while maintaining a Buy rating.
You May Also Be Interested In
- Citi Upgrades Ferrovial SA (FER:SM) (FRRVF) to Buy
- Climb Global Solutions (CLMB) PT Raised to $50 at Freedom Broker
- Ideaya Biosciences (IDYA) PT Lowered to $57 at Truist Securities
Create E-mail Alert Related Categories
Analyst PT ChangeSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
